Exelixis Inc (EXEL)
Exelixis is an oncology company that engages in creating medicines and combination regimens for cancer care. Co.'s products include: CABOMETYX® (cabozantinib) tablets, which are approved both alone and in combination with Bristol-Myers Squibb Company's OPDIVO® (nivolumab) for renal cell carcinoma; COMETRIQ® (cabozantinib) capsules, which are approved for progressive, metastatic medullary thyroid cancer; COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.
EXEL SEC Filing Email Alerts Service
| Company Name: |
Exelixis Inc |
| Website: |
www.exelixis.com |
| Sector: |
Drugs & Pharmaceuticals |
| Number of ETFs Holding EXEL: |
70 |
| Total Market Value Held by ETFs: |
$1.19B |
| Total Market Capitalization: |
$7.20B |
| % of Market Cap. Held by ETFs: |
16.50% |
|
|
May 1, 2024 • 9:19 PM Eastern
Strong Buy (3.53 out of 4)
60th percentile
|
|
Free EXEL Email Alerts:
